Sun’s ‘Game Changing’ Dengue Drug May Launch In Four Years
This article was originally published in PharmAsia News
India's Sun Pharma has said it is developing a drug derived from traditional Indian medicine that could be a ‘game-changer’ in treating dengue, one of the most rapidly spreading mosquito-borne viral diseases in the world with no current treatment.
You may also be interested in...
Newly published details of interim clinical data for Takeda's candidate vaccine for dengue show activity across all serotypes that seems to bode well for an ongoing Phase III trial with the potential rival to the only currently available vaccine, Sanofi's Dengvaxia.
India's top-ranked drug firm Sun Pharma is vying for a play in the dengue vaccines space via a collaboration with the non-profit research organization, International Centre for Genetic Engineering and Biotechnology. The partners expect their vaccine candidate to potentially best live-attenuated dengue vaccine candidates, including Sanofi's Dengvaxia.
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.